SOT106 wins FDA orphan-drug and Fast Track designations for two sarcoma indications
AI Summary- SOT106 received FDA designations for soft tissue sarcoma and osteosarcoma.
- SOT106 now holds both ODD and FTD for each of its two indications.
- Sotio plans to start clinical trials and administer the first patient dose within the year.